139183-91-8

Basic information

• Product Name: Methyl 5,6,7,8-tetrahydroiMidazo[1,5-a]pyridine-6-carboxylate
• Synonyms: Methyl 5,6,7,8-tetrahydroiMidazo[1,5-a]pyridine-6-carboxylate
• CAS NO: 139183-91-8
• Molecular Formula: C9H12N2O2
• Molecular Weight: 180.20378
• Mol File: 139183-91-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 5,6,7,8-tetrahydroiMidazo[1,5-a]pyridine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5,6,7,8-tetrahydroiMidazo[1,5-a]pyridine-6-carboxylate(139183-91-8)
• EPA Substance Registry System: Methyl 5,6,7,8-tetrahydroiMidazo[1,5-a]pyridine-6-carboxylate(139183-91-8)

Safety Data

• Hazardous Substances Data: 139183-91-8(Hazardous Substances Data)

Usage

General Description

Methyl 5,6,7,8-tetrahydroiMidazo[1,5-a]pyridine-6-carboxylate is a chemical compound with the molecular formula C11H14N2O2. It is a derivative of the heterocyclic compound imidazo[1,5-a]pyridine and contains a methyl ester group and a carboxylate group. Methyl 5,6,7,8-tetrahydroiMidazo[1,5-a]pyridine-6-carboxylate is used in medicinal chemistry and drug development, particularly in the synthesis of pharmaceuticals with potential therapeutic applications. It has also been studied for its potential biological activities and pharmacological properties. However, further research is needed to fully understand its potential uses and effects.

Relevant articles and documents

Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives

We prepared a novel series of conformationally restricted fused imidazole derivatives 4b, 4c and 4d (possessing 4,5,6,7-tetrahydroimidazo[4,5- c]pyridine and substituted 4,5,6,7-tetrahydro-1H-benzimidazole for 4b, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine for 4c and 5,6,7,8- tetrahydroimidazo[1,5-a]pyridine for 4d as a basic amine part and (2- methoxyphenyl)aminocarbonyl group as an aromatic-carbonyl part). Their activities were then evaluated as an 5-hydroxytryptamine (5-HT3) receptor antagonist which may be useful for the treatment of irritable bowel syndrome (IBS) as well as for nausea and vomiting associated with cancer chemotherapy. The most potent compound was N-(2-methoxyphenyl)-4,5,6,7-tetrahydro-1H- benzimidazole-5-carboxamide 14 in this series with an ID50 value of 0.32 μg/kg on the von Bezold-Jarisch reflex in rats and an IC50 value of 0.43 μM on the isolated colonic contraction in guinea pig, approximately ten and two times more potent than ondansetron 1, respectively. The structure- activity relationships (SAR) study suggested that the high potency of 14 may be attributed to the suitable position and direction of the N-C-N centroid in the conformationally restricted imidazole ring against the planar (2-methoxy- phenyl)aminocarbonyl part in the binding of 14 to the receptor.